Researchers of a study examined the incidence of tardive dyskinesia (TD) between long-acting injectable antipsychotics (LAI-APs) and equivalent oral antipsychotics (O-APs), LAI first-generation antipsychotics and LAI second-generation antipsychotics (LAI-SGAs), as well as individual LAI-APs using the Japanese Adverse Drug Event Report with data from April 2004 to February 2021. Researchers included 8,425 patients in the study. It was found that LAI-APs, especially LAI-SGAs, compared with O-APs may be linked to a lower TD risk.